• Humans
• Cataract/complications
• Cataract Extraction
• Diabetes Complications
• Lens Implantation, Intraocular
• Phacoemulsification

• Central Retinal Artery Occlusion
• Management
• Retinal Artery Occlusion
• Systematic Review
• Treatment
• Branch Retinal Artery Occlusion

• branch retinal vein occlusion
• central retinal vein occlusion
• dexamethasone intravitreal implant
• macular edema
• retinal vein occlusion

• AbbVie

• Anti-vascular endothelial growth factor
• Antimetabolites
• Glaucoma
• Glaucoma drainage implants
• Mitomycin

• Humans
• Glaucoma Drainage Implants
• Mitomycin/administration & dosage
• Angiogenesis Inhibitors/administration & dosage
• Angiogenesis Inhibitors/therapeutic use
• Vascular Endothelial Growth Factor A/antagonists & inhibitors
• Glaucoma/surgery
• Glaucoma/physiopathology
• Glaucoma/drug therapy
• Intraocular Pressure/physiology
• Alkylating Agents/administration & dosage
• Treatment Outcome

• Universidade do Porto

• anti‐VEGF
• intraocular pressure
• laser speckle flowgraphy
• reliability
• reproducibility
• retinal blood flow
• wild type mouse

• Animals
• Mice
• Receptors, Vascular Endothelial Growth Factor/administration & dosage
• Mice, Inbred C57BL
• Intravitreal Injections
• Retinal Vessels/diagnostic imaging
• Retinal Vessels/physiopathology
• Diabetic Retinopathy/physiopathology
• Diabetic Retinopathy/drug therapy
• Diabetic Retinopathy/diagnosis
• Recombinant Fusion Proteins/administration & dosage
• Diabetes Mellitus, Experimental/physiopathology
• Regional Blood Flow/physiology
• Laser-Doppler Flowmetry/methods
• Angiogenesis Inhibitors/administration & dosage
• Reproducibility of Results
• Vascular Endothelial Growth Factor A/antagonists & inhibitors
• Blood Flow Velocity/physiology
• Male
• Intraocular Pressure/physiology
• Intraocular Pressure/drug effects
• Optic Disk/blood supply

• CNIG14NOV005 National Medical Research Council
• 2017_SERI NMRC/CG-INCEPTOR/Pre-Clinical Core Platform

• Ahmed glaucoma valve implantation
• anti-vascular endothelial growth factor
• meta-analysis
• neovascular glaucoma
• systematic review

• Diabetic retinopathy
• Glaucoma
• Neovascular
• Nomogram
• Retinopathy
• Risk factors

• Baerveldt glaucoma implant
• Supramid ripcord stent
• neovascular glaucoma

• female
• humans
• male
• middle aged
• bevacizumab
• bevacizumab/therapeutic use
• glaucoma, neovascular
• glaucoma, neovascular/drug therapy
• ranibizumab
• ranibizumab/therapeutic use
• vascular endothelial growth factor a
• vascular endothelial growth factor a/antagonists & inhibitors

• Female
• Humans
• Male
• Middle Aged
• Bevacizumab/therapeutic use
• Glaucoma, Neovascular/drug therapy
• Ranibizumab/therapeutic use
• Vascular Endothelial Growth Factor A/antagonists & inhibitors

• UG1 EY020522 NEI NIH HHS

• Anti-VEGF
• Meta-analysis
• Neovascular glaucoma
• Randomised controlled trial
• Surgical
• Systematic review

For verifying the prognosis of Lucentis-assisted vitrectomy (PPV) in diabetic retinopathy (DR) and neovascular glaucoma (NVG), a retrospective analysis of DR and NVG patients who were admitted to our hospital from July 2019 to December 2020 was conducted. According to the treatment protocol, subjects who had PPV intervention were in the control group (CG; n = 38) and those receiving Lucentis adjunctive PPV were included in the intervention group (RG; n = 40). The indicators between groups were listed: treatment success rate, postoperative complication rate, surgical outcome indicators, BCVA, intraocular pressure (IOP) change, foveal thickness, and VEGF level in aqueous humor. Indicators in RG were obviously higher than in CG, such as treatment success rate and surgical outcome indicators. Conversely, lower postoperative complication rate, postoperative BCVA, IOP, retinal fovea thickness, and VEGF level in aqueous humor were found in RG than in CG. Therefore, the study reached the following conclusions about vitrectomy assisted by Lucentis: (1) it effectively increases the success rate of treatment, decreases postoperative complications as well as surgical risks, and improves patients' vision; (2) it promotes the recovery of IOP, reduces macular edema and VEGF levels in aqueous humor, and inhibits the neonatal formation of blood vessels. It is finally confirmed that Lucentis adjuvant PPV in the treatment of DR complicated with NVG is safe and feasible.

We evaluated the long-term efficacy and surgical outcomes of Ahmed glaucoma valve (AGV) implantation in patients with refractory glaucoma by glaucoma type.

In total, 135 eyes of 135 patients diagnosed with refractory glaucoma and underwent AGV implantation between 2002 and 2018 were reviewed retrospectively. The best-corrected visual acuity (BCVA), intraocular pressure (IOP), and number of antiglaucoma medications were investigated at baseline and follow-up. The cumulative probability of qualified success according to the glaucoma type was evaluated at 12, 24, 36, and 60 months postoperatively.

The mean IOP of all patients was 35.7 ± 11.7 mmHg, which was significantly reduced 12.7 ± 7.0 mmHg at 1 week, 16.2 ± 7.5 mmHg at 2 weeks, 17.6 ± 6.8 mmHg at 1 month, 17.5 ± 6.4 mmHg at 3 months, 16.1 ± 6.0 mmHg at 6 months, 16.7 ± 8.0 mmHg at 12 months, 16.4 ± 6.6 mmHg at 24 months, 15.6 ± 5.0 mmHg at 36 months, and 15.6 ± 5.6 mmHg at 60 months after surgery (p < 0.001, respectively). The mean number of antiglaucoma medications was 3.7 ± 1.3, which significantly decreased to 0.4 ± 0.9 at 1 week, 0.3 ± 0.8 at 2 weeks, 0.7 ± 0.9 at 1 month, 1.1 ± 1.1 at 3 months, 1.4 ± 1.0 at 6 months, 1.5 ± 1.1 at 12 months, 1.6 ± 1.2 at 24 months, 1.7 ± 1.2 at 36 months, and 1.8 ± 1.3 at 60 months after surgery (p < 0.001, respectively). The mean BCVA significantly improved from postoperative 2 weeks. Although 71 (52.6%) eyes had postoperative complications, the cumulative probability of surgical success was 72.6% at 12 months, 66.7% at 24 months, and 63.7% at 36 and 60 months. According to the glaucoma type, the success rate of AGV implantation was more than 50% even after 60 months follow-up, except subgroup of neovascular glaucoma (NVG) due to retinal vein occlusion (RVO).

AGV implantation in patients with refractory glaucoma was, after long-term follow-up, successful overall. Therefore, AGV implantation can be an effective surgical option to reduce the IOP and number of antiglaucoma medications and to improve visual acuity for various glaucoma types.

• Ahmed glaucoma valve
• Intraocular pressure
• Refractory glaucoma

To assess the risk for capsular rupture during routine phacoemulsification in patients with a history of anti-VEGF injections and other possible risk modifiers such as treatment patterns, type of anti-VEGF agent, and experience of the surgeon, among others.

This study reviewed the medical records of 11,129 patients from 7 different hospitals in 5 countries. The study included 939 patients that underwent routine phacoemulsification and had a history of anti-VEGF therapy. We excluded patients with known risk factors for capsular rupture, as well as patients with a history of other retinal procedures. The study extracted data regarding general demographics, the number of previous injections, type of anti-VEGF agent, details of cataract surgery, and anti-VEGF treatment patterns.

Overall prevalence of posterior capsular rupture: 7.45% (95% CI: 5.9–9.32%). The mean number of injections per patient was 3.37 ± 2.8. More than 50% of the patients received their last anti-VEGF injection within three months before cataract surgery. The complication rate during intravitreal injections was 1.07%. In the univariate analysis, the experience of the cataract surgeon (inexperience surgeons; OR: 2.93) and the history of prior anti-VEGF therapy (OR: 1.77) were significant risk indicators for PCR (p < 0.05). However, after controlling for age in the multivariate analysis, the trend did not reach a statistical significance.

The risk for capsular rupture is higher in patients with a history of intravitreal anti-VEGF injections.

To investigate the expression of vascular endothelial growth factor (VEGF)-C and vascular endothelial growth factor receptor (VEGFR)3 in the trabecular meshwork (TM) of patients with glaucoma and cultured TM cells. Methods: The expressions of VEGF-C in angle tissues collected by trabeculectomy from patients with glaucoma and non-glaucomatous choroidal malignant melanoma were analyzed by immunohistochemistry. Additionally, VEGF-C concentrations were determined in the aqueous humor of patients with glaucoma by ELISA. The expressions of VEGFR3, which is a receptor of VEGF-C in cultured TM cells, were analyzed by Western blot analysis and immunocytochemistry. Cultured TM cells were stimulated by oxidative stress, hypoxia, or high glucose conditions, and VEGF-C concentrations in supernatants and cell lysates were determined by ELISA. Results: VEGF-C immunoreactivity was positive in TM tissues of glaucoma patients, but not in those of non-glaucomatous controls. VEGF-C concentrations in the aqueous humor of patients with neovascular glaucoma and primary open-angle glaucoma were lower than those with non-glaucoma patients. VEGFR3 was expressed in cultured TM cells. VEGF-C concentrations in supernatants or cell lysates of TM cells cultured under oxidative stress and hypoxia were significantly elevated compared with those under steady conditions (p < 0.05). VEGF-C concentrations in supernatants and cell lysates of TM cells cultured in high glucose were significantly higher than those in low glucose (p < 0.01). Conclusions: VEGF-C was expressed in TM tissues of patients with glaucoma, which was secreted from cultured TM cells under various pathological conditions. These results suggest that VEGF-C may be involved in the pathology of glaucoma.

• VEGF-C
• VEGFR3
• neovascular glaucoma
• primary open-angle glaucoma
• trabecular meshwork

• anti-vascular endothelial growth factor therapy
• conbercept
• neovascular glaucoma
• silicone oil
• vitrectomy

• age-related macular degeneration
• anti-VEGF
• etiopathogenesis
• future advancements
• gene-therapy
• neovascular age-related macular degeneration
• risk factors

• Animals
• Biomarkers
• Clinical Trials as Topic
• Disease Management
• Disease Susceptibility
• Humans
• Inflammasomes/metabolism
• Macular Degeneration/etiology
• Macular Degeneration/metabolism
• Macular Degeneration/pathology
• Macular Degeneration/therapy
• Molecular Targeted Therapy
• NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
• Prevalence
• Retinal Neovascularization/etiology
• Retinal Neovascularization/metabolism
• Risk Assessment
• Risk Factors
• Treatment Outcome

• Antiangiogenic drug
• Inflammation
• Proliferative retinopathy
• Rubeosis iridis
• UPARANT

• Endothelial Growth Factors
• Glaucoma, Neovascular/drug therapy
• Humans
• Intraocular Pressure/drug effects
• Randomized Controlled Trials as Topic
• Vascular Endothelial Growth Factor A/antagonists & inhibitors
• Visual Acuity/drug effects

• UG1 EY020522 NEI NIH HHS